Quinolone-based third-line therapy for Helicobacter pylori eradication

Journal of Clinical Biochemistry and Nutrition

Volumn 44, Issue 2, 2009, Pages 119-124

  Nishizawa, Toshihiro ^a   Suzuki, Hidekazu ^a   Hibi, Toshifumi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Helicobacter pylori; Quinolone; Third line therapy

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; GATIFLOXACIN; LEVOFLOXACIN; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RABEPRAZOLE; RIFABUTIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTHRALGIA; BACTERIAL INFECTION; BACTERIUM CULTURE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENCY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERADICATION THERAPY; HELICOBACTER PYLORI; HUMAN; METALLIC TASTE; MULTIDRUG RESISTANCE; MUTATIONAL ANALYSIS; MYALGIA; NAUSEA; PATIENT COMPLIANCE; PHOTOTOXICITY; QT PROLONGATION; REVIEW; SEIZURE; TASTE DISORDER; TREATMENT DURATION;

HELICOBACTER PYLORI;

EID: 63049096015     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.08-220R     Document Type: Review

References (37)

1. Suzuki, H., Hibi, T., and Marshall, B.J.: Helicobacter pylori: present status and future prospects in Japan. J. Gastroenterol., 42, 1-15, 2007.
2. Suzuki, H., Masaoka, T., Nomura, S., Hoshino, Y., Kurabayashi, K., Minegishi, Y., Suzuki, M., and Ishii, H.: Current consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease. Keio J. Med., 52, 163-173, 2003.
3. Asaka, M., Sugiyama, T., Kato, M., Satoh, K., Kuwayama, H., Fukuda, Y., Fujioka, T., Takemoto, T., Kimura, K., Shimoyama, T., Shimizu, K., and Kobayashi, S.: A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter, 6, 254-261, 2001.
4. Masaoka, T., Suzuki, H., Kurabayashi, K., Kamiya, A.G., and Ishii, H.: Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis. Aliment. Pharmacol. Ther., 20 Suppl 1, 68-73, 2004.
5. Adamek, R.J., Suerbaum, S., Pfaffenbach, B., and Opferkuch, W.: Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin - influence on treatment outcome. Am. J. Gastroenterol., 93, 386-389, 1998.
6. Matsuhisa, T., Kawai, T., Masaoka, T., Suzuki, H., Ito, M., Kawamura, Y., Tokunaga, K., Suzuki, M., Mine, T., Takahashi, S., and Sakaki, N.: Efficacy of metronidazole as second-line drug for the treatment of Helicobacter pylori Infection in the Japanese population: a multicenter study in the Tokyo Metropolitan Area. Helicobacter, 11, 152-158, 2006.
7. Masaoka, T., Suzuki, H., Kurabayashi, K., Nomoto, Y., Nishizawa, T., Mori, M., and Hibi, T.: Could frameshift mutation in the frxA and rdxA genes of Helicobacter pylori be a marker for metronidazole resistance?. Aliment. Pharmacol. Ther., 24 (Suppl. 4), 81-87, 2006.
8. Nishizawa, T., Suzuki, H., Masaoka, T., Iwasaki, E., and Hibi, T.: A New Eradication Resistance Index as a Predictor of Metronidazole-Containing Second-Line Treatment of Helicobacter pylori. Digestion, 76, 215-220, 2007.
9. Malfertheiner, P., Megraud, F., O'Morain, C., Hungin, A.P., Jones, R., Axon, A., Graham, D.Y., and Tytgat, G.: Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment. Pharmacol. Ther., 16, 167-180, 2002.
10. Gisbert, J.P., Gisbert, J.L., Marcos, S., Moreno-Otero, R., and Pajares, J.M.: Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment. Pharmacol. Ther., 24, 1469-1474, 2006.
11. Cianci, R., Montalto, M., Pandolfi, F., Gasbarrini, G.B., and Cammarota, G.: Third-line rescue therapy for Helicobacter pylori infection. World J. Gastroenterol., 12, 2313-2319, 2006.
12. Sharara, A.I., Chaar, H.F., Aoun, E., Abdul-Baki, H., Araj, G.F., and Kanj, S.S.: Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication. Helicobacter, 11, 231-236, 2006.
13. Tanaka, M., Isogai, E., Isogai, H., Hayashi, S., Hirose, K., Kimura, K., Sugiyama, T., and Sato, K.: Synergic effect of quinolone antibacterial agents and proton pump inhibitors on Helicobacter pylori. J. Antimicrob. Chemother., 49, 1039-1040, 2002.
14. Kim, J.M., Kim, J.S., Kim, N., Kim, S.G., Jung, H.C., and Song, I.S.: Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients. Int. J. Antimicrob. Agents, 28, 6-13, 2006.
15. Miyachi, H., Miki, I., Aoyama, N., Shirasaka, D., Matsumoto, Y., Toyoda, M., Mitani, T., Morita, Y., Tamura, T., Kinoshita, S., Okano, Y., Kumagai, S., and Kasuga, M.: Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan. Helicobacter, 11, 243-249, 2006.
16. Rafeey, M., Ghotaslou, R., Nikvash, S., and Hafez, A.A.: Primary resistance in Helicobacter pylori isolated in children from Iran. J. Infect. Chemother., 13, 291-295, 2007.
17. Toro, C., Garcia-Samaniego, J., Carbo, J., Iniguez, A., Alarcon, T., Lopez-Brea, M., and Baquero, M.: [Prevalence of primary Helicobacter pylori resistance to eight antimicrobial agents in a hospital in Madrid]. Rev. Esp. Quimioter, 14, 172-176, 2001.
18. Zou, J., Yang, Z.X., and Qin, Z.M.: [Laboratory and clinical study of levofloxacin against Helicobacter pylori]. Zhonghua Yi Xue Za Zhi, 83, 1778-1781, 2003.
19. Zullo, A., Perna, F., Hassan, C., Ricci, C., Saracino, I., Morini, S., and Vaira, D.: Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. Aliment. Pharmacol. Ther., 25, 1429-1434, 2007.
20. Boyanova, L., Stancheva, I., Spassova, Z., Katzarov, N., Mitov, I., and Koumanova, R.: Primary and combined resistance to four antimicrobial agents in Helicobacter pylori in Sofia, Bulgaria. J. Med. Microbiol., 49, 415-418, 2000.
21. Sherif, M., Mohran, Z., Fathy, H., Rockabrand, D.M., Rozmajzl, P.J., and Frenck, R.W.: Universal high-level primary metronidazole resistance in Helicobacter pylori isolated from children in Egypt. J. Clin. Microbiol., 42, 4832-4834, 2004.
22. Nishizawa, T., Suzuki, H., Kurabayashi, K., Masaoka, T., Muraoka, H., Mori, M., Iwasaki, E., Kobayashi, I., and Hibi, T.: Gatifloxacin resistance and mutations in gyrA after unsuccessful Helicobacter pylori eradication in Japan. Antimicrob. Agents. Chemother., 50, 1538-1540, 2006.
23. Cabrita, J., Oleastro, M., Matos, R., Manhente, A., Cabral, J., Barros, R., Lopes, A.I., Ramalho, P., Neves, B.C., and Guerreiro, A.S.: Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J. Antimicrob. Chemother., 46, 1029-1031, 2000.
24. Moore, R.A., Beckthold, B., Wong, S., Kureishi, A., and Bryan, L.E.: Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob. Agents Chemother., 39, 107-111, 1995.
25. Nishizawa, T., Suzuki, H., Umezawa, A., Muraoka, H., Iwasaki, E., Masaoka, T., Kobayashi, I., and Hibi, T.: Rapid detection of point mutations conferring resistance to fluoroquinolone in gyrA of Helicobacter pylori by allele-specific PCR. J. Clin. Microbiol., 45, 303-305, 2007.
26. Zullo, A., Hassan, C., De Francesco, V., Lorenzetti, R., Marignani, M., Angeletti, S., Ierardi, E., and Morini, S.: A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication. Dig. Liver Dis., 35, 232-236, 2003.
27. Gisbert, J.P., Castro-Fernandez, M., Bermejo, F., Perez-Aisa, A., Ducons, J., Fernandez-Bermejo, M., Bory, F., Cosme, A., Benito, L.M., Lopez-Rivas, L., Lamas, E., Pabon, M., and Olivares, D.: Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. Am. J. Gastroenterol., 101, 243-247, 2006.
28. Hsu, P.I., Wu, D.C., Chen, A., Peng, N.J., Tseng, H.H., Tsay, F.W., Lo, G.H., Lu, C.Y., Yu, F.J., and Lai, K.H.: Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures. Eur. J. Clin. Invest., 38, 404-409, 2008.
29. Sanchez, J.E., Saenz, N.G., Rincon, M.R., Martin, I.T., Sanchez, E.G., and Martinez, M.J.: Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones. J. Antimicrob. Chemother., 46, 283-285, 2000.
30. Rhomberg, P.R., Biedenbach, D.J., and Jones, R.N.: Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp. Diagn. Microbiol. Infect. Dis., 40, 45-49, 2001.
31. Otani, T., Tanaka, M., Ito, E., Kurosaka, Y., Murakami, Y., Onodera, K., Akasaka, T., and Sato, K.: In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone. Antimicrob. Agents Chemother., 47, 3750-3759, 2003.
32. Gisbert, J.P. and Morena, F.: Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment. Pharmacol. Ther., 23, 35-44, 2006.
33. Nishizawa, T., Suzuki, H., Nakagawa, I., Iwasaki, E., Masaoka, T., and Hibi, T.: Gatifloxacin-based triple therapy as third-line regimen for Helicobacter pylori eradication. J. Gastroenterol. Hepatol., 23 (Suppl. 2), 167-170, 2008.
34. Haerian, H., McHugh, P., Brown, R., Somes, G., and Solomon, S.S.: Gatifloxacin produces both hypoglycemia and hyperglycemia: a retrospective study. Am. J. Med. Sci., 335, 95-98, 2008.
35. Suzuki, H., Nishizawa, T., Muraoka, H., and Hibi, T.: Sitafloxacin and garenoxacin may overcome the antibiotic resistance of H. pylori with gyrA mutation. Antimicrob. Agents Chemother., 53, Feb 2. 2009 [Epub ahead of print].
36. Miehlke, S., Hansky, K., Schneider-Brachert, W., Kirsch, C., Morgner, A., Madisch, A., Kuhlisch, E., Bastlein, E., Jacobs, E., Bayerdorffer, E., Lehn, N., and Stolte, M.: Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Aliment. Pharmacol. Ther., 24, 395-403, 2006.
37. Suzuki, S., Suzuki, H., Nishizawa, T., Kaneko, F., Ootani, S., Muraoka, H., Saito, Y., Kobayashi, I., and Hibi, T.: Past rifampicin dosing determines rifabutin resistance of H. pylori. Digestion, 79, 1-4, 2009.